Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the efficacy and safety of re-treatment with anticholinergics on refractory idiopathic overactive bladder (OAB) previously treated with intravesical botulinum neurotoxin type A (BTX-A) injections. Methods: One hundred patients were initially managed by intravesical injections of 100 IU of BTX-A. After the effects of BTX-A faded, patients were randomized into 2 groups: group A patients received solifenacin (10 mg) for 12 weeks (study group), while group B patients received placebo treatment for 12 weeks (control group), then subsequently received solifenacin (10 mg) for another 6 weeks. All patients underwent preoperative urodynamic testing. Patients were asked to complete the validated overactive bladder symptoms score (OABSS) and incontinence quality of life (I-QoL) instruments after the effects of intravesical BTX-A faded and at 12 weeks of follow-up. Univariate and multivariate analyses of the factors affecting treatment response were conducted. Results: At 12 weeks of follow-up, in group A, all OABSS items, including the total score, had improved significantly (P<0.0001). Group A had lower frequency and amplitude of detrusor overactivity and detrusor leak point pressure (P<0.0001, P=0.03, and P=0.01, respectively). Cystometric capacity also increased significantly (P=0.007), as did all I-QoL parameters. In a comparison of patients with failed treatment and patients with successful treatment, female sex, repeated intravesical BTX-A injections, and increased bladder capacity were statistically significant (P=0.001, P=0.0001, and P=0.002, respectively). Repeated intravesical BTX-A injections and increased bladder capacity were independent factors predicting treatment success. Conclusions: In patients with refractory idiopathic OAB, reuse of anticholinergics could be an effective treatment option in patients after the effects of BTX-A fade. Repeated intravesical BTX-A injections and increased cystometric capacity could affect treatment response.
Abstract
Purpose: To evaluate the efficacy and safety of re-treatment with anticholinergics on refractory idiopathic overactive bladder (OAB) previously treated with intravesical botulinum neurotoxin type A (BTX-A) injections. Methods: One hundred patients were initially managed by intravesical injections of 100 IU of BTX-A. After the effects of BTX-A faded, patients were randomized into 2 groups: group A patients received solifenacin (10 mg) for 12 weeks (study group), while group B patients received placebo treatment for 12 weeks (control group), then subsequently received solifenacin (10 mg) for another 6 weeks. All patients underwent preoperative urodynamic testing. Patients were asked to complete the validated overactive bladder symptoms score (OABSS) and incontinence quality of life (I-QoL) instruments after the effects of intravesical BTX-A faded and at 12 weeks of follow-up. Univariate and multivariate analyses of the factors affecting treatment response were conducted. Results: At 12 weeks of follow-up, in group A, all OABSS items, including the total score, had improved significantly (P<0.0001). Group A had lower frequency and amplitude of detrusor overactivity and detrusor leak point pressure (P<0.0001, P=0.03, and P=0.01, respectively). Cystometric capacity also increased significantly (P=0.007), as did all I-QoL parameters. In a comparison of patients with failed treatment and patients with successful treatment, female sex, repeated intravesical BTX-A injections, and increased bladder capacity were statistically significant (P=0.001, P=0.0001, and P=0.002, respectively). Repeated intravesical BTX-A injections and increased bladder capacity were independent factors predicting treatment success. Conclusions: In patients with refractory idiopathic OAB, reuse of anticholinergics could be an effective treatment option in patients after the effects of BTX-A fade. Repeated intravesical BTX-A injections and increased cystometric capacity could affect treatment response.
참고문헌 (29)
- Abrams P, "Muscarinic receptors : their distribution and function in body systems, and the implications for treating overactive bladder", Br J Pharmacol, 148, pp.565~578 (2006)
- Apostolidis A, "Can we create a valid treatment algorithm for patients with drug resistant overactive bladder(OAB)syndrome or detrusor overactivity(DO)? Results from a think tank(ICI-RS 2015)", Neurourol Urodyn, 36, pp.882~893 (2017)
- Uvin P, "Chronic administration of anticholinergics in rats induces a shift from muscarinic to purinergic transmission in the bladder wall", Eur Urol, 64, pp.502~510 (2013)
- Dolly O, "Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins", Headache, 43(Suppl 1), pp.S16~24 (2003)
- Apostolidis A, "Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity", Eur Urol, 49, pp.644~650 (2006)
- Mangera A, "Contemporary management of lower urinary tract disease with botulinum toxin A : a systematic review of botox(onabotulinumtoxinA)and dysport(abobotulinumtoxinA)", Eur Urol, 60, pp.784~795 (2011)
- Gormley EA, "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA", SUFU guideline, 2012, pp.188(6 Suppl), 2455~2463
- Datta SN, "Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration", J Urol, 184, pp.2578~2585 (2010)
- Leippold T, "Botulinum toxin as a new therapy option for voiding disorders : current state of the art", Eur Urol, 44, pp.165~174 (2003)
- Elbaset MA, "Validation of the Arabic linguistic version of the overactive bladder symptoms score questionnaire", Arab J Urol, pp.1~5 (2019)[DOI]
- Patrick DL, "Quality of life of women with urinary incontinence : further development of the incontinence quality of life instrument(I-QOL)", Urology, 53, pp.71~76 (1999)
- Schäfer W, "Good urodynamic practices : uroflowmetry, filling cystometry, and pressure-flow studies", Neurourol Urodyn, 21, pp.261~274 (2002)
- Chapple CR, "Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder", BJU Int, 93, pp.303~310 (2004)
- Vardy MD, "Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes : results from VIBRANT-a double-blind, placebo-controlled trial", Int J Clin Pract, 63, pp.1702~1714 (2009)
- Bowalekar SK, "Non-inferiority and equivalence trials : Need for a standardized process", Perspect Clin Res, 2, pp.115~118 (2011)
- Yamaguchi O, "Latest treatment for lower urinary tract dysfunction : therapeutic agents and mechanism of action", Int J Urol, 20, pp.28~39 (2013)
- Toozs-Hobson P, "Detrusor overactivity--an update", BJOG, 111(Suppl 1), pp.53~56 (2004)
- Visco AG, "Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence", N Engl J Med, 367, pp.1803~1813 (2012)
- Wein AJ, "Diagnosis and treatment of the overactive bladder", Urology, 62(5 Suppl 2), pp.20~27 (2003)
- Marcelissen TA, "Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms", World J Urol, 35, pp.307~311 (2017)
- Chapple C, "OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence : a randomised, double-blind, placebo-controlled trial", Eur Urol, 64, pp.249~256 (2013)
- Chohan N, "Efficacy and duration of response to botulinum neurotoxin A(onabotulinumA)as a treatment for detrusor overactivity in women", Int Urogynecol J, 26, pp.1605~1612 (2015)
- Hashim H, "Patient preferences for treating refractory overactive bladder in the UK", Int Urol Nephrol, 47, pp.1619~1627 (2015)
- Grise P, "Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy : comparison of two doses", Eur Urol, 58, pp.759~766 (2010)
- Cardozo L, "Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder", J Urol, 172(5 Pt 1), pp.1919~1924 (2004)
- Apostolidis A, "Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014", Neurourol Urodyn, 35, pp.293~298 (2016)
- Toglia MR, "Solifenacin for overactive bladder : patient-reported outcomes from a large placebo-controlled trial", Postgrad Med, 121, pp.151~158 (2009)
- Garely AD, "Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder : the VESIcare Open-Label Trial(VOLT)", Clin Ther, 28, pp.1935~1946 (2006)
- Anger JT, "Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms : a systematic review of the literature", J Urol, 183, pp.2258~2264 (2010)